Jonathan Krell
Experienced in Kaposi Sarcoma

Jonathan Krell

Du Cane Road, 
London, ENG, GB 
Experienced in Kaposi Sarcoma
Du Cane Road, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Jonathan Krell practices in London, United Kingdom. Mr. Krell is rated as an Experienced expert by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreaticoduodenectomy, and Endoscopy.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Kaposi Sarcoma.

Gender
Male

Locations

Du Cane Road, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, TAK228
Study Phase: Phase 2
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

143 Total Publications

Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.
Journal: Future oncology (London, England)
Published: November 29, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Krell's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile